Eduovisual
Respiratory
COPD: long-term oxygen and pulmonary rehab referral
— 3rd leading cause of death in the US; ~16 million diagnosed adults, many more undiagnosed
— Smoking is the dominant risk factor (≥10 pack-years); also consider biomass exposure, occupational dust, α1-antitrypsin deficiency in <45 yo or basilar emphysema
— Advanced COPD (GOLD 3–4, FEV1 <50% predicted) with dyspnea on minimal exertion, cyanosis, or polycythemia
— Signs of cor pulmonale: peripheral edema, elevated JVP, loud P2, RV heave
— Morning headaches, daytime somnolence (suggest hypercapnia)
— Resting SpO2 ≤92% on room air in the clinic → triggers formal resting ABG or oximetry assessment
— Long-term oxygen therapy (LTOT): only proven to ↓ mortality in severe resting hypoxemia
— Pulmonary rehabilitation: improves dyspnea, exercise tolerance, QoL, and reduces readmissions in symptomatic patients regardless of oxygenation
— The ambulatory clinician is the gatekeeper for both referrals; failure to refer eligible patients is a quality-of-care gap tracked by CMS and value-based programs
— Smoking cessation remains the only intervention besides LTOT (in qualifying patients) and lung volume reduction surgery shown to reduce mortality
Board pearl: Suspect LTOT eligibility in any COPD patient with resting SpO2 ≤88% or PaO2 ≤55 mmHg — but never prescribe oxygen during an acute exacerbation; re-assess after 60–90 days of optimized stable therapy because hypoxemia often resolves with treatment of the acute insult.
Key distinction: LTOT prolongs life only in resting hypoxemia; pulmonary rehab improves life but does not extend it — both are complementary, not interchangeable.
— Progressive dyspnea (mMRC ≥2: "walks slower than peers" or "stops for breath after 100 m")
— Chronic productive cough, recurrent winter bronchitis
— Exercise intolerance with self-imposed activity restriction ("I stopped gardening")
— ≥2 moderate exacerbations or ≥1 hospitalization in the prior year
— Smoking status and pack-years; current vaping/cannabis use
— Home environment: stairs, oxygen-incompatible heat sources, smokers in household (fire/safety risk with O2)
— Functional status: 6-minute walk distance if available, ADLs, falls
— Sleep symptoms: snoring, witnessed apneas, morning headache — screen for overlap syndrome (COPD + OSA) which raises nocturnal desaturation risk
— Mood: depression and anxiety prevalence ~40% in advanced COPD; treat to enable rehab participation
— mMRC ≥2 or CAT ≥10
— Post-hospitalization within 4 weeks of an exacerbation (strongest mortality and readmission benefit)
— Self-reported activity avoidance, deconditioning spiral
— Influenza annually, COVID-19 boosters, PCV20 or PCV15+PPSV23, RSV vaccine if ≥60, Tdap, zoster
— Occupational dust, mold, indoor biomass cooking
Step 3 management: At every chronic-care COPD visit, document mMRC dyspnea score, exacerbation count in past 12 months, current inhaler technique, smoking status, and resting SpO2 — these five items drive every downstream decision (escalation of inhalers, rehab referral, LTOT evaluation).
Board pearl: A patient discharged after a COPD exacerbation should be referred to pulmonary rehab within 4 weeks — this window has the strongest evidence for reducing 1-year mortality and readmission.
— Pursed-lip breathing, tripod posture, accessory muscle use
— Cachexia in emphysema-predominant ("pink puffer") vs cyanosis/edema in bronchitis-predominant ("blue bloater") — older terms but still flagged on boards
— Barrel chest, ↓ cricosternal distance (<3 cm)
— Resting SpO2 on room air after ≥5 minutes seated rest; recheck on ambulation (6-minute walk or hallway walk)
— Document SpO2 nadir and recovery time
— Beware falsely high SpO2 in carboxyhemoglobinemia (current smokers) — pulse oximeter cannot distinguish COHb from O2Hb; if suspicious, get an ABG with co-oximetry
— Dark skin pigmentation may overestimate SpO2 by 2–3% — have a lower threshold for ABG confirmation before denying LTOT
— ↓ Breath sounds, prolonged expiratory phase, end-expiratory wheeze
— Hyperresonance to percussion
— Loud P2, parasternal heave, RV S3
— Elevated JVP, hepatojugular reflux, hepatomegaly, dependent edema
— Clubbing is not typical of COPD — if present, search for lung cancer, bronchiectasis, or ILD
— 6-minute walk test: distance <350 m predicts higher mortality; desaturation ≥4% or to ≤88% during the walk identifies exertional hypoxemia candidates for ambulatory O2
Key distinction: Resting hypoxemia (SpO2 ≤88%) → continuous LTOT, mortality benefit proven. Exertional-only hypoxemia → ambulatory O2 may improve symptoms but LOTT trial (2016) showed no mortality or hospitalization benefit for moderate desaturation alone.
Board pearl: Digital clubbing in a COPD patient = workup for lung cancer until proven otherwise; order a chest CT.
— Post-bronchodilator FEV1/FVC <0.70 confirms COPD
— FEV1 % predicted defines GOLD severity: GOLD 1 ≥80%, GOLD 2 50–79%, GOLD 3 30–49%, GOLD 4 <30%
— Repeat every 1–2 years for trend; do not repeat during exacerbations
— Resting SpO2 ≤88% on room air → obtain ABG to confirm PaO2 before prescribing LTOT (Medicare requires documentation)
— ABG also detects hypercapnia (PaCO2 ≥52 mmHg with pH ≥7.30) — qualifies select stable patients for home NIV/BPAP
— Repeat ABG/SpO2 60–90 days after exacerbation recovery before committing to lifelong O2
— CXR: hyperinflation, flattened diaphragms, increased AP diameter
— Low-dose chest CT annually for lung cancer screening in adults 50–80 yo with ≥20 pack-years who currently smoke or quit within 15 years (USPSTF 2021)
— CBC: secondary polycythemia (Hct >55%) suggests chronic hypoxemia; eosinophilia ≥300/µL favors ICS responsiveness
— BMP, BNP if cor pulmonale suspected
— α1-antitrypsin level once in every COPD patient (WHO/GOLD recommendation), especially <45 yo or basilar disease
— Right axis deviation, P pulmonale, multifocal atrial tachycardia in advanced disease
— Polysomnography if overlap syndrome features or nocturnal desaturation despite adequate daytime SpO2
Step 3 management: Medicare LTOT qualification — document on room air, at rest, awake, ≥2 measurements over 3 weeks (or single measurement post-discharge with re-test in 60–90 days): PaO2 ≤55 mmHg or SpO2 ≤88%; OR PaO2 56–59/SpO2 89% with cor pulmonale, P pulmonale on ECG, or Hct >55%.
Board pearl: Never qualify a patient for LTOT based on an ABG drawn during a hospitalization for exacerbation — always re-assess after stabilization.
— Two qualifying SpO2/PaO2 measurements separated in time during clinical stability
— Some payers accept a single qualifying value at discharge with mandatory re-test at 60–90 days; if normalized off oxygen, discontinue LTOT — chronic prescribing of unneeded O2 is a quality issue and fall/fire hazard
— Indicated when daytime SpO2 is borderline (89–93%) and there is unexplained polycythemia, cor pulmonale, morning headaches, or pulmonary HTN out of proportion to spirometry
— Threshold for nocturnal O2: SpO2 ≤88% for ≥5 minutes or ≥10% of total sleep time
— Identifies exertional desaturation
— Establishes baseline before pulmonary rehab and post-rehab improvement
— Screen for pulmonary hypertension when RV failure signs, refractory edema, or hypoxemia disproportionate to spirometry
— TR jet velocity, RV size/function, estimated PASP
— Right heart catheterization confirms group 3 PH if therapy decision hinges on it (rarely changes management in pure COPD)
— Quantifies emphysema distribution — relevant for lung volume reduction surgery, endobronchial valves, or transplant referral
— Rules out concomitant bronchiectasis, ILD, lung cancer
— Pulmonology: GOLD 3–4, frequent exacerbations, AAT deficiency, suspected overlap syndrome, transplant consideration (FEV1 <30%, hypercapnia, PH)
CCS pearl: On a CCS case of stable COPD, after confirming spirometry and severity, advance the clock 60–90 days post-exacerbation before ordering repeat ABG/SpO2 to qualify LTOT — ordering it during the acute presentation will be flagged as premature.
Key distinction: Echo-estimated PASP screens for PH; right heart cath confirms — but in pure COPD, PH-specific vasodilators are not indicated and may worsen V/Q mismatch.
— Combines symptom burden (mMRC or CAT) with exacerbation history
— Group A: low symptoms (mMRC 0–1, CAT <10), ≤1 moderate exacerbation, no hospitalizations → bronchodilator
— Group B: high symptoms, ≤1 moderate exacerbation → LABA+LAMA
— Group E: ≥2 moderate exacerbations or ≥1 hospitalization → LABA+LAMA (add ICS if eos ≥300)
— Smoking cessation
— LTOT in qualifying severe resting hypoxemia
— Lung volume reduction surgery in selected upper-lobe emphysema with low exercise capacity
— Pulmonary rehab post-exacerbation (within 4 weeks)
— Possibly LABA+LAMA+ICS triple therapy in frequent exacerbators with eosinophilia (ETHOS, IMPACT)
— mMRC ≥2 or CAT ≥10
— Post-exacerbation (any severity)
— Pre/post lung surgery
— Typically 6–12 weeks, ≥2 sessions/week, supervised exercise + education + nutrition + psychosocial support
— Covered by Medicare Part B for moderate–very severe COPD (FEV1/FVC <0.70 and FEV1 <80%); up to 36 sessions, occasionally 72
— Goal: SpO2 ≥90% at rest, sleep, and exertion
— Continuous use ≥15 hours/day required for mortality benefit (NOTT, MRC trials)
— Titrate flow separately for rest, exertion, and sleep — typical starting flow 1–2 L/min via nasal cannula
Step 3 management: A patient with FEV1 30% predicted, CAT 18, one hospitalization last year, and resting SpO2 90% on room air should receive LABA+LAMA, pulmonary rehab referral, vaccines, smoking cessation, and an action plan — but not LTOT (does not meet criteria).
Board pearl: Rehab improves dyspnea, QoL, and reduces readmissions more than any single inhaler — refer early and often.
— SABA (albuterol) or SAMA (ipratropium) PRN for all patients
— LAMA (tiotropium, umeclidinium, glycopyrrolate) — reduces exacerbations more than LABA
— LABA (salmeterol, formoterol, olodaterol, indacaterol)
— Combine LABA+LAMA for Group B and Group E
— Add to LABA+LAMA (triple therapy) when:
— ≥2 moderate exacerbations/year or ≥1 hospitalization despite dual bronchodilation
— Blood eosinophils ≥300/µL (or ≥100 with frequent exacerbations)
— Concomitant asthma–COPD overlap
— Avoid as monotherapy; ICS in COPD ↑ pneumonia risk — counsel patient
— Chronic bronchitis phenotype, FEV1 <50%, frequent exacerbations
— SE: weight loss, diarrhea, depression — screen for suicidality
— Former smokers with frequent exacerbations on optimal inhaled therapy
— Baseline ECG (QTc), audiogram; check for NTM colonization
— Varenicline (most effective single agent), bupropion SR, NRT combinations
— Combine pharmacotherapy + behavioral counseling at every visit
— Prescribe device (concentrator, portable cylinders, liquid O2), flow rates for rest/exertion/sleep, hours/day
— Document indication, baseline PaO2/SpO2, follow-up plan
Key distinction: ICS in asthma = first-line and protective; ICS in COPD = adjunct for exacerbation-prone eosinophilic phenotype, raises pneumonia risk. Don't reflexively add ICS to every COPD patient.
Board pearl: A COPD patient with new pneumonia and recent ICS escalation — review eosinophils and exacerbation history; if criteria for ICS are weak, deprescribe the ICS.
— Stationary concentrator: home use, up to 5 L/min, electricity-dependent — counsel on power outage plan
— Portable O2 concentrator (POC): pulse-dose delivery; verify it maintains SpO2 ≥90% during ambulation
— Compressed gas cylinders / liquid O2: backup and high-flow needs
— Nasal cannula standard; transtracheal O2 (rare) or reservoir cannulas for high flow requirements
— Emerging option for hypercapnic COPD with frequent exacerbations; not yet standard
— Stable hypercapnic COPD with PaCO2 ≥52 mmHg → high-intensity NIV reduces mortality and hospitalization (HOT-HMV trial)
— Distinct from CPAP for OSA
— Supervised aerobic + resistance exercise (treadmill, cycle, weights), 2–3×/week × 6–12 weeks
— Inspiratory muscle training in selected patients
— Education: inhaler technique, action plan, energy conservation, breathing techniques (pursed-lip, diaphragmatic)
— Nutritional counseling (BMI <21 is a poor prognostic marker)
— Psychosocial: CBT for anxiety/depression
— Smoking cessation reinforcement
— Lung volume reduction surgery (LVRS): upper-lobe predominant emphysema, low post-rehab exercise capacity — mortality benefit (NETT trial subgroup)
— Endobronchial valves: similar physiology, less invasive, requires intact interlobar fissure
— Lung transplantation: FEV1 <20%, hypercapnia, PH, BODE 7–10
— Absolutely no smoking in the home (fire, burns, fatalities documented)
— Secure cylinders upright; keep ≥6 feet from open flames/heat
— Notify fire department of home O2 use
CCS pearl: When you start LTOT, also order home health evaluation, written action plan, and follow-up in 30–90 days with repeat SpO2/ABG to confirm continued need and titrate flow.
— Polypharmacy: review anticholinergic burden — LAMAs add to total load; consider falls risk
— Dexterity and cognition determine inhaler choice: soft-mist inhalers (Respimat) and nebulizers for arthritis, tremor, or cognitive impairment; DPIs require adequate inspiratory flow (often inadequate post-exacerbation or in very advanced disease)
— Frailty does not disqualify rehab — modified, seated, or home-based rehab is effective and may be preferable
— Annual lung cancer screening only until life expectancy and functional status support workup/treatment of a finding (shared decision-making)
— Most inhaled bronchodilators have minimal systemic absorption; no dose adjustment usually needed
— Tiotropium and other LAMAs: caution in severe renal impairment (CrCl <60), though typically still used
— Avoid theophylline (narrow therapeutic index, renal clearance variable)
— Roflumilast: not recommended in severe hepatic impairment (Child-Pugh B/C)
— Roflumilast contraindicated in moderate–severe hepatic dysfunction
— Azithromycin: caution with hepatotoxicity history
— Diuretics carefully — over-diuresis ↓ RV preload and ↓ cardiac output
— Treat underlying hypoxemia (LTOT) first; PH-specific vasodilators not indicated in group 3 PH from COPD (may worsen V/Q mismatch)
— Common in older COPD; treat OSA with CPAP — may obviate or supplement nighttime O2
Key distinction: In a frail elderly COPD patient on LAMA + amitriptyline + oxybutynin + diphenhydramine — total anticholinergic burden contributes to falls and delirium; deprescribe the non-essential anticholinergics, not the LAMA (which has mortality and exacerbation benefit).
Board pearl: A DPI requires a peak inspiratory flow ≥60 L/min — if the elderly patient can't achieve it, switch to a soft-mist or nebulized formulation.
— COPD itself is rare in reproductive-age women, but α1-antitrypsin deficiency may present
— Continue most inhalers (LABA, ICS, ipratropium considered low-risk); avoid roflumilast and varenicline if cleaner alternatives suffice
— Treat hypoxemia aggressively — fetal oxygenation depends on maternal SpO2 ≥95%; LTOT thresholds are stricter in pregnancy
— Smoking cessation is the single highest-yield intervention; behavioral therapy preferred, NRT shared decision
— Suspect with COPD <45 yo, basilar emphysema, family history, or coexistent liver disease
— Quantitative AAT level + phenotype/genotype (PiZZ most severe)
— Augmentation therapy (IV pooled human AAT) for severe deficiency with established lung disease
— Genetic counseling for family
— Burn pit, asbestos, silica, coal — affects disability determination and screening (low-dose CT, occupational pulmonology referral)
— LTOT and rehab access often limited; refer to community programs, manufacturer patient-assistance for inhalers
— Medicaid coverage of pulmonary rehab varies by state — verify
— Low-dose opioids (morphine 1–2 mg PO or 0.5 mg SC) for refractory dyspnea
— Fans, breathing techniques, anxiolytics
— Hospice eligibility: FEV1 <30%, frequent ER visits, resting hypoxemia, cor pulmonale, unintentional weight loss
— Air travel: SpO2 <92% at sea level → predicts in-flight hypoxemia; hypoxic altitude simulation test (HAST) guides in-flight O2 prescription
— Patients on LTOT need airline-approved POC and advance notice
Step 3 management: Always screen one-time for α1-antitrypsin deficiency in any patient diagnosed with COPD — current GOLD/ATS recommendation; misses are a frequent board trap.
— Acute exacerbations (AECOPD): viral or bacterial triggers; risk factor for further exacerbations and 1-year mortality up to 25% after a hospitalized episode
— Pneumonia (especially with ICS)
— Pulmonary hypertension and cor pulmonale → RV failure, edema, hepatic congestion
— Secondary erythrocytosis (Hct >55%) — therapeutic phlebotomy rarely; treat the hypoxemia
— Spontaneous pneumothorax in bullous emphysema
— Lung cancer — leading cause of death in mild–moderate COPD; ensure annual LDCT screening
— Cachexia and sarcopenia (poor prognosis)
— Anxiety, depression, social isolation
— Osteoporosis (steroids, inactivity, smoking) — screen with DXA
— Burns and house fires (smoking-related): preventable, leading cause of LTOT death
— Nasal/mucosal drying, epistaxis — humidify if flow ≥4 L/min, saline spray
— Equipment tripping/fall hazard
— Hypercapnia worsening with high FiO2 in CO2-retainers — titrate to SpO2 88–92% in known retainers
— Patient nonadherence: <40% use O2 ≥15 h/day in real-world cohorts → loss of mortality benefit
— Generally very safe; transient desaturation during exercise — adjust O2 flow
— Musculoskeletal soreness; rare cardiac events (screen with baseline ECG/symptom review)
— Adherence/transportation barriers — telerehab is an emerging covered option
— LAMA: urinary retention, dry mouth, narrow-angle glaucoma exacerbation
— LABA: tachycardia, tremor
— ICS: pneumonia, oral candidiasis, dysphonia
— Roflumilast: weight loss, mood changes
Board pearl: In a hospitalized AECOPD patient who develops worsening somnolence after O2 is uptitrated, check ABG for CO2 retention; do not simply lower O2 — consider NIV/BPAP. Target SpO2 88–92% in suspected retainers.
— GOLD 3–4 (FEV1 <50%)
— ≥2 exacerbations/year or any hospitalization
— Diagnostic uncertainty (asthma vs COPD vs ILD)
— α1-antitrypsin deficiency
— Candidate for LVRS, endobronchial valves, or transplant evaluation
— Suspected pulmonary hypertension
— Failure to improve despite optimized therapy
— Marked ↑ symptoms (rest dyspnea), new cyanosis, peripheral edema, altered mental status
— Failure to respond to initial outpatient therapy
— Significant comorbidities (heart failure, arrhythmia, pneumonia)
— Inadequate home support
— Hypoxemia worsening or new hypercapnia/acidosis
— Severe dyspnea inadequately responding to initial therapy
— Mental status change, persistent or worsening hypoxemia (PaO2 <40 mmHg) despite supplemental O2
— Respiratory acidosis pH <7.25 despite NIV
— Need for invasive mechanical ventilation
— Hemodynamic instability
— Respiratory acidosis (pH ≤7.35, PaCO2 ≥45)
— Severe dyspnea with accessory muscle use
— Persistent hypoxemia despite supplemental O2
— Contraindications: cardiac/respiratory arrest, severe altered mental status, vomiting/aspiration risk, recent facial/upper GI surgery, copious secretions
— Follow-up within 7–14 days (CMS quality metric)
— Refer to pulmonary rehab within 4 weeks
— Verify inhaler technique, medication reconciliation, action plan
— Smoking cessation reinforcement, vaccinations updated
CCS pearl: On a CCS AECOPD admission, expected orders include: controlled O2 (target SpO2 88–92%), nebulized SABA+SAMA, systemic corticosteroids (prednisone 40 mg × 5 days), antibiotics if increased sputum purulence/volume or mechanical ventilation, NIV for respiratory acidosis, and schedule pulmonary rehab + 7–14 day follow-up before discharge.
— Reversible airflow obstruction (FEV1 ↑ ≥12% and 200 mL post-bronchodilator)
— Younger, atopy, episodic
— Rarely causes chronic resting hypoxemia
— ICS is first-line (opposite of COPD)
— Features of both; often ICS + LABA + LAMA
— Higher exacerbation burden; consider biologics if eosinophilic
— Chronic productive cough with copious purulent sputum, recurrent infections
— HRCT shows airway dilation, tram-tracks, signet-ring sign
— Treat underlying cause (CF, immunodeficiency, post-infectious, NTM)
— Airway clearance, inhaled antibiotics; rehab also indicated
— Sweat chloride, genetic testing; CFTR modulators
— Bronchiectasis, malabsorption, infertility
— Restrictive pattern on PFTs (↓TLC, ↑FEV1/FVC), velcro crackles, clubbing
— HRCT: subpleural reticulation, honeycombing
— Antifibrotics (nintedanib, pirfenidone); rehab improves QoL; LTOT criteria same as COPD
— BMI ≥30 + awake hypercapnia + sleep-disordered breathing
— Treat with weight loss, PAP therapy, not O2 alone
— Unexplained dyspnea, V/Q scan with mismatched defects
— Pulmonary endarterectomy potentially curative
Key distinction: Reversibility is the asthma hallmark; persistent post-bronchodilator FEV1/FVC <0.70 is the COPD hallmark. Both can have chronic hypoxemia, but LTOT criteria are identical. Inhaler approach diverges — ICS first in asthma, LAMA/LABA first in COPD.
Board pearl: Bibasilar fine "velcro" crackles + clubbing + restrictive PFTs → think IPF, not COPD, regardless of smoking history.
— Orthopnea, PND, S3, elevated BNP, pulmonary edema on CXR
— Echo distinguishes
— Treat HF; coexists with COPD in 20–30%
— Idiopathic, connective tissue disease, HIV, portopulmonary
— RHC for diagnosis; PAH-specific therapy (endothelin antagonists, PDE5i, prostacyclins) — distinct from group 3 PH of COPD
— Causes exertional dyspnea without hypoxemia (SpO2 normal); CBC easily screens
— Common, diagnosis of exclusion; rehab equivalent (graded exercise) is therapeutic
— Restrictive pattern with normal lung parenchyma; supine vital capacity drop, MIP/MEP reduced
— Home NIV often indicated
— Restrictive physiology, may need NIV
— In current smokers, falsely normal SpO2; co-oximetry needed
— Inspiratory stridor mimics wheeze, normal PFTs between episodes
— Common comorbidity in COPD; can mimic exacerbation
— New focal symptoms, hemoptysis, weight loss, clubbing
— Annual LDCT screening for eligible patients
Step 3 management: A COPD patient with worsening dyspnea out of proportion to FEV1 decline → echocardiogram (HF, PH), CBC (anemia), BNP, and reassessment of inhaler technique and adherence before escalating COPD therapy.
Key distinction: Group 1 PAH responds to vasodilators; group 3 PH (COPD-related) does not — treat the underlying COPD, address hypoxemia with O2.
— Smoking cessation (every visit, every time): 5 A's, varenicline/bupropion/NRT, behavioral counseling
— LTOT if criteria met, ≥15 h/day
— LABA+LAMA ± ICS per GOLD ABE
— Pulmonary rehab referral
— Vaccines: annual influenza, COVID-19 boosters, PCV20 (or PCV15→PPSV23), RSV ≥60, Tdap, zoster ≥50
— Optimized inhalers + correct technique (assess at every visit)
— Written action plan with rescue prednisone/antibiotic prescription for self-initiation in selected patients
— Roflumilast or azithromycin for refractory exacerbators
— Smoking cessation, avoid triggers, indoor air quality
— Cardiovascular: statin if indicated, BP control, cardio-selective beta-blockers are safe in COPD when needed for CV disease
— Osteoporosis: DXA, calcium/vitamin D, bisphosphonates as indicated
— Depression/anxiety: PHQ-9, GAD-7; SSRIs and CBT
— Nutrition: avoid underweight (BMI <21); pulmonary cachexia is a poor prognostic sign
— Annual LDCT for ages 50–80 with ≥20 pack-years currently smoking or quit ≤15 years (USPSTF 2021)
— Goals of care, code status, POLST, healthcare proxy — initiate early in advanced COPD, not in crisis
— Inhaler reconciliation + technique
— 7–14 day follow-up appointment
— Pulmonary rehab referral within 4 weeks
— Smoking cessation
— Vaccination update
— Written action plan
— Home O2 assessment with plan for re-test in 60–90 days
Board pearl: Cardio-selective beta-blockers (metoprolol, bisoprolol) are not contraindicated in COPD and may improve survival in patients with concomitant HF or CAD — a frequent board trap.
— Stable mild–moderate COPD: every 6–12 months
— Moderate–severe or on LTOT: every 3–6 months
— Post-exacerbation: within 7–14 days, then 4–6 weeks
— Post-rehab completion: maintenance plan within 1 month
— mMRC dyspnea, CAT score
— Exacerbations since last visit (#, severity, hospitalizations)
— Smoking status and cessation interventions offered
— Inhaler technique observed
— Resting SpO2 on room air (or current O2 setting)
— Vaccination status
— Medication adherence and side effects
— Functional status, depression screen
— Re-test ABG/SpO2 at 60–90 days post-initiation (if started after hospitalization) — discontinue if no longer qualifying
— Annual reassessment thereafter
— Verify ≥15 h/day adherence
— Check device function, flow accuracy
— Educate on smoking/fire safety repeatedly
— Travel and altitude planning
— 6-minute walk distance (minimal clinically important difference ~25–30 m)
— CAT/SGRQ score
— Mood (PHQ-9, HADS)
— Self-reported exacerbations and hospitalizations
— Adherence to home exercise post-program
— Inhaler technique demonstration with placebo device
— Action plan: recognize early exacerbation, when to start rescue meds, when to call/seek care
— Energy conservation, pursed-lip and diaphragmatic breathing
— Sexual health and dyspnea management
— Nutrition (small frequent meals, protein)
— Caregiver education
Step 3 management: A patient finishes 8 weeks of pulmonary rehab — what next? Prescribe a home maintenance exercise program, reassess at 3 months, consider re-enrollment if decline; gains plateau without continued activity.
Board pearl: A patient on LTOT who quit smoking and whose AECOPD is now 6 months in the past — re-check ABG/SpO2; ~30–40% no longer meet criteria and O2 can be stopped.
— Active smoking is not an absolute contraindication to LTOT per Medicare, but it is a major fire/burn hazard
— Document repeated counseling, fire safety education, and smoke-detector presence
— Some institutions require signed safety agreements; many clinicians defer LTOT until cessation given documented fatalities
— Notify local fire department of home O2 use
— Patient safety pearl: Home O2 + smoking is a leading preventable cause of severe burns and house fires — repeated, documented counseling is both clinical and medicolegal protection
— LTOT is lifestyle-altering (tethered to equipment, social stigma, travel limits) — discuss tradeoffs
— Lung cancer screening: discuss benefits, false positives, incidental findings, downstream procedures
— Advance care planning: avoid initiating intubation discussions in crisis; have the conversation in clinic
— High-risk handoff: medication reconciliation errors, missed rehab referrals, missed O2 reassessment are top causes of readmission
— Use a standardized discharge bundle and confirm 7–14 day follow-up was actually scheduled (not just ordered)
— Telephone outreach within 48–72 hours of discharge reduces readmission
— Severe COPD patients may have intermittent hypercapnic encephalopathy affecting capacity; assess at baseline and document
— Withdraw of LTOT at end of life is ethically permissible with informed patient/surrogate consent — comfort-focused care with low-dose opioids for dyspnea
— Document functional limitations objectively (FEV1, 6MWD, SpO2 on exertion) for disability determinations
— LTOT and rehab access lag in rural, minority, and low-income populations — actively address transportation, telerehab, durable medical equipment coverage
Key distinction: Withholding O2 from an actively smoking patient is not legally required, but failing to document fire-safety counseling exposes the clinician to liability if injury occurs.
Board pearl: "Which intervention prolongs life in this COPD patient?" — if SpO2 ≤88% at rest, the answer is continuous oxygen therapy; if SpO2 >88%, it's smoking cessation.
— Stem: 68 yo discharged after AECOPD, SpO2 86% on RA at discharge. Next best step?
— Answer: Start O2 at discharge and repeat ABG/SpO2 in 60–90 days to confirm need; do not commit to lifelong O2 yet
— Stem: Stable COPD, FEV1 45%, resting SpO2 90%, exertional desaturation to 86%. Prescribe continuous O2?
— Answer: No mortality/hospitalization benefit demonstrated; consider ambulatory O2 for symptoms only; focus on rehab and inhalers
— Stem: 70 yo discharged 2 weeks ago after AECOPD, now in clinic, dyspnea limits activity. Best intervention?
— Answer: Pulmonary rehabilitation referral (within 4 weeks of discharge)
— Stem: Patient on LTOT continues to smoke; family alarmed. Next step?
— Answer: Intensive cessation counseling + pharmacotherapy + fire safety education; document — not automatic discontinuation
— Stem: COPD on LABA+LAMA+ICS, recurrent pneumonia, eos 80, exacerbations decreased. Next step?
— Answer: De-escalate ICS (low eos, no clear indication, raising pneumonia risk)
— Stem: Post-MI patient with COPD — withhold metoprolol? Answer: No, continue cardio-selective beta-blocker
— Stem: 40 yo nonsmoker with basilar emphysema. Next test? Answer: AAT level
— Stem: PaCO2 56 stable, frequent admissions. Best add-on? Answer: Home BPAP
— End-stage COPD, optimized therapy, dyspnea persists. Answer: Low-dose oral morphine
— Patient readmitted within 30 days; what was missed? Answer typically: pulmonary rehab referral, inhaler technique, 7–14 day follow-up, or smoking cessation
Step 3 management: Memorize the post-discharge bundle — boards love testing the 4-week rehab referral window and the 60–90 day LTOT reassessment.
In moderate-to-severe COPD, continuous long-term oxygen therapy (≥15 h/day) prolongs life only when resting SpO2 ≤88% or PaO2 ≤55 mmHg (or 56–59/89% with cor pulmonale, P pulmonale, or polycythemia), while pulmonary rehabilitation — ideally within 4 weeks of any exacerbation — improves dyspnea, exercise capacity, quality of life, and reduces readmissions in nearly every symptomatic COPD patient.
— LTOT: qualify with two stable measurements (or one + 60–90 day re-test post-exacerbation); target SpO2 ≥90% at rest, sleep, and exertion; ≥15 h/day; mortality benefit (NOTT/MRC) only in severe resting hypoxemia, not moderate desaturation (LOTT)
— Pulmonary rehab: refer if mMRC ≥2 / CAT ≥10 or after any exacerbation; 6–12 weeks of supervised exercise + education + nutrition + psychosocial care; Medicare covers up to 36 (–72) sessions for FEV1/FVC <0.70 and FEV1 <80%
— Post-AECOPD discharge bundle: inhaler reconciliation + technique, 7–14 day follow-up, rehab referral within 4 weeks, smoking cessation, vaccinations, written action plan, plan for O2 reassessment at 60–90 days — drives CMS readmission metrics
— Mortality-modifying interventions in COPD (memorize): smoking cessation, LTOT in qualifying patients, pulmonary rehab post-exacerbation, LVRS in selected upper-lobe emphysema, possibly triple inhaler therapy in eosinophilic frequent exacerbators, home NIV for stable hypercapnic disease — everything else (most inhalers, roflumilast, azithromycin) improves symptoms and exacerbations but not survival
Board pearl: When in doubt on a Step 3 COPD vignette, the highest-value next step is almost always smoking cessation, pulmonary rehab referral, or correct inhaler technique — not another inhaler.